Essex Woodlands Management, Inc. - Q2 2020 holdings

$204 Million is the total value of Essex Woodlands Management, Inc.'s 8 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .

 Value Shares↓ Weighting
RVNC  REVANCE THERAPEUTICS INC$81,613,000
+65.0%
3,342,0470.0%40.04%
+25.7%
VERO BuyVENUS CONCEPT, INC.$43,338,000
+74.0%
12,417,856
+76.9%
21.26%
+32.6%
EYPT  EYEPOINT PHARMACEUTICALS INC$31,851,000
-25.5%
41,909,2190.0%15.62%
-43.2%
AXGN  AXOGEN INC$22,453,000
-11.2%
2,429,9990.0%11.02%
-32.3%
TELA BuyTELA BIO, INC.$18,037,000
+114.7%
1,391,768
+29.6%
8.85%
+63.6%
MNOV  MEDICINOVA INC$5,994,000
+45.7%
1,105,9410.0%2.94%
+11.0%
CBIO  CATALYST BIOSCIENCES INC$462,000
+34.3%
78,6220.0%0.23%
+2.7%
ELGXQ  ENDOLOGIX INC$101,000
+13.5%
125,7470.0%0.05%
-12.3%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MEDICINOVA INC42Q3 20236.5%
REVANCE THERAPEUTICS INC39Q3 202344.6%
AXOGEN INC26Q4 202143.3%
ENDOLOGIX INC24Q1 201922.5%
ABIOMED INC20Q1 201852.1%
CORIUM INTL INC20Q1 201923.5%
TELA BIO, INC.16Q3 202331.5%
VENUS CONCEPT, INC.16Q3 202321.3%
ACURA PHARMACEUTICALS INC15Q1 20191.4%
CATALYST BIOSCIENCES INC15Q1 20191.0%

View Essex Woodlands Management, Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View Essex Woodlands Management, Inc.'s complete filings history.

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings